Healio
SearchLoading
Healio
SearchLoading

OSN New York and OSN New York Retina
ByDavid Esposito
ByAnthony DeFino
Fact checked byChristine Klimanskis, ELS

Read more

October 24, 2023
1 min watch
Save

VIDEO: ONL1204 demonstrates promising results in geographic atrophy

ByDavid Esposito
ByAnthony DeFino
Fact checked byChristine Klimanskis, ELS

Healio
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions and subtitles off, selected

      NEW YORK — In this Healio Video Perspective from OSN New York’s Disruptive Innovations Symposium, David Esposito, CEO of ONL Therapeutics, discusses results of ONL1204 in geographic atrophy.

      “It’s a small peptide delivered via [intravitreal] injection, and we’re across three clinical programs: one in geographic atrophy, one in open-angle glaucoma and one in retinal detachment,” he said.

      Sources/Disclosures

      Collapse
      Source:

      Healio Interviews

      Disclosures: Esposito reports being the CEO of ONL Therapeutics.

      Read more from OSN New York and OSN New York Retina

      View all

      Read more about

      retinal detachment
      geographic atrophy
      open-angle glaucoma
       

      Related Content